

29th January, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Script Code: 500259

National Stock Exchange of India Limited
Exchange Plaza, G. Block, Bandra Kurla
Complex, Bandra (East),
Mumbai - 400 051

Script Code: LYKALABS

Dear Sir/Madam,

Sub: Outcome of the Board Meeting – 29th January, 2026

Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the SEBI Listing Regulations)

With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in their meeting held today i.e. 29th January, 2026, has *inter-alia*, considered, approved and taken on record the following:

Unaudited Financial Results for the third quarter ended 31st December, 2025

Unaudited Financial Results (Standalone & Consolidated) for the third quarter ended 31st December, 2025 alongwith Limited Review Report thereon is enclosed herewith as **Annexure -1**.

The above information will also be available on the website of the Company at www.lykalabs.com.
The meeting of the Board of Directors commenced at 3:15 pm and concluded at 5.17 pm.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**


Shailendra Agrawal
Company Secretary and Compliance Officer
Encl.: as above

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Lyka Labs Limited** (the "Company") for the quarter ended December 31, 2025 and year to date from April 1, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Regn No. 105335W


Mehul N. Patel
(Partner)
Membership No. 132650

UDIN: 26132650BUBVGU7450

Place: Mumbai
Date: 29th January, 2026



Statement of Standalone Unaudited Financial Results for the Quarter and Nine Month Ended 31st December 2025

(₹ in lakhs)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	December/25 (Unaudited)	September/25 (Unaudited)	December/24 (Unaudited)	December/25 (Unaudited)	December/24 (Unaudited)	March-25 (Audited)
I Revenue						
Revenue from Operations	3072.79	3297.04	3292.11	9287.46	10418.09	13469.74
Other Income	125.80	121.47	87.43	313.94	162.32	234.35
II Total Income	3198.59	3418.51	3379.54	9601.40	10580.41	13704.09
III Expenses						
(a) Cost of Materials Consumed	733.00	896.91	941.73	2434.85	2739.64	3707.18
(b) Purchase of Stock in trade	430.10	325.15	320.28	980.11	1542.10	1752.37
(c) Change in inventories of Finished Goods, work-in-progress and stock-in-trade	(7.75)	23.50	(3.07)	31.72	(78.76)	(137.31)
(d) Employee benefits expense	941.93	1032.76	833.47	2872.09	2457.39	3409.02
(e) Finance Costs	81.59	78.57	61.62	245.26	178.42	230.45
(f) Depreciation and amortisation expense	207.63	207.12	175.44	618.11	511.48	645.31
(g) Other expenses	784.25	1334.17	691.12	2754.01	2309.80	2949.60
Total Expenses	3170.75	3898.18	3020.60	9936.15	9660.08	12556.62
IV Profit / (Loss) before Exceptional Items and Taxes (II - III)	27.84	(479.67)	358.94	(334.75)	920.33	1147.47
V Exceptional Items (Net)	0.00	0.00	0.00	0.00	0.00	0.00
VI Profit / (Loss) before Tax	27.84	(479.67)	358.94	(334.75)	920.33	1147.47
VII Tax Expenses						
Current Tax	0.00	18.00	86.00	49.00	210.41	272.41
Deferred Tax	(0.15)	(134.99)	3.09	(130.47)	17.82	52.34
VIII Net Profit / (Loss) after Tax	27.99	(362.68)	269.85	(253.29)	692.10	822.72
IX Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)	(1.85)	0.00	0.00	(1.85)	0.00	18.22
X Total Comprehensive Income / (Loss)	26.14	(362.68)	269.85	(255.14)	692.10	840.94
Paid up Equity Share Capital (FV ₹ 10/- each)	3569.00	3569.00	3569.00	3569.00	3569.00	3569.00
Other Equity						9925.09
XI Basic and diluted earnings per share	0.08	(1.02)	0.75	(0.71)	1.93	2.28

Notes:

- The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 29th January 2026
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the Unaudited Standalone financials results for the quarter & nine Month ended 31st December, 2025.
- During the quarter under review, the Company has paid a premium of ₹217.14 lakhs on 1,08,570 preference shares, redeemed on 30th September 2025. The said premium has been adjusted against the General Reserve.
- Effective from 21st November 2025, the Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes. On the basis of best available information, the Company has assessed the one time incremental impact of Rs. 11.41 Lakhs in the above financial results under Employee Benefit Expenses for the quarter and nine months ended 31st December 2025. The Company continues to monitor the finalisation of Central / State Government Rules and clarifications in relation to newly introduced Labour Code and would provide appropriate accounting effect if any on the basis of new developments.



For Lyka Labs Limited


 Konat Gandhi
 Managing Director & CEO
 DIN: 01516156

Mumbai : 29th January 2026

Independent Auditor's Review Report on the Quarterly and Year-to-Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Lyka Labs Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Lyka Labs Limited** ("the Parent"), which includes its subsidiaries (the Parent and its Subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2025 and year-to-date from April 1, 2025 to December 31, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

- i) Lyka Labs Limited

Subsidiaries

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/ information reflects total revenues of Rs. 15.89 lakhs and Rs. 1077.86 lakhs, total net profit/ (loss) after tax of Rs. (43.11) lakhs and Rs. 16.34 lakhs and total comprehensive income of Rs. (43.11) lakhs and Rs. 16.34 lakhs, for the quarter ended December 31, 2025 and year-to-date from April 1, 2025 to December 31, 2025 respectively, which have been reviewed by us.



6. Based on our review conducted and procedures performed as stated in para 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D. Kothary & Co.
Chartered Accountants
Firm Registration No. 105335W


Mehul N. Patel
(Partner)
Membership No. 132650

UDIN: 26132650HINQKE7847



Place: Mumbai
Date: 29th January, 2026

Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Month Ended 31st December 2025

Particulars		Quarter Ended			Nine Year Ended		(₹ in lakhs)
		Dec/25	Sep/25	Dec/24	Dec/25	Dec/24	Year Ended
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Unaudited)	Mar/25
I	Revenue						
	Revenue from Operations	3,072.80	3,666.05	3,379.76	10,041.39	10,506.67	13,849.54
	Other Income	116.22	109.35	82.62	288.66	141.16	223.17
II	Total Income	3,189.02	3,775.40	3,462.38	10,330.05	10,647.83	14,072.71
III	Expenses						
(a)	Cost of Materials Consumed	733.00	896.91	941.73	2,434.85	2,739.64	3,707.18
(b)	Purchase of Stock in trade	430.09	567.43	367.33	1,450.52	1,589.82	1,987.95
(c)	Change in inventories of finished goods, work-in-progress and stock-in-trade	(7.75)	23.41	(3.07)	31.55	(78.76)	(135.96)
(d)	Employee benefits expense	948.91	1,039.86	848.47	2,893.61	2,502.14	3,463.26
(e)	Finance Costs	81.64	78.87	61.43	245.89	180.44	227.25
(f)	Depreciation and amortisation expense	215.46	214.95	183.31	641.59	535.27	676.93
(g)	Other expenses	803.68	1,392.46	705.96	2,951.36	2,368.58	3,033.61
	Total Expenses	3,205.03	4,213.89	3,105.17	10,649.37	9,837.14	12,960.22
IV	Profit / (Loss) before Exceptional Items and Taxes (II - III)	(16.01)	(438.49)	357.21	(319.32)	810.69	1,112.49
V	Exceptional Items (Net)	-	-	-	-	-	-
VI	Profit / (Loss) before Tax	(16.01)	(438.49)	357.21	(319.32)	810.69	1,112.49
VII	Tax Expenses						
	Current Tax / Earlier Year Tax	-	18.00	86.24	49.00	210.65	272.65
	Deferred Tax	(0.89)	(135.05)	0.57	(131.39)	9.58	46.52
VIII	Net Profit / (Loss) after Tax	(15.12)	(321.44)	270.40	(236.93)	590.46	793.32
IX	Other Comprehensive Income	(1.85)	-	(1.75)	(1.85)	-	18.09
X	Total Comprehensive Income / (Loss)	(16.97)	(321.44)	268.65	(238.78)	590.46	811.41
XI	Profit After Tax Attributed to						
	Owners of the Parent	(0.03)	(335.74)	269.92	(242.50)	624.04	801.20
	Non-controlling Interest	(15.10)	14.30	0.48	5.56	(33.58)	(7.88)
		(15.12)	(321.44)	270.40	(236.94)	590.46	793.32
XII	Other Comprehensive Income						
	Owners of the Parent	(1.85)	-	(1.44)	(1.85)	-	18.14
	Non-controlling Interest	-	-	(0.31)	-	-	(0.05)
		(1.85)	-	(1.75)	(1.85)	-	18.09
XIII	Total Comprehensive Income / (Loss)						
	Owners of the Parent	(1.87)	(335.74)	268.48	(244.35)	624.04	819.34
	Non-controlling Interest	(15.10)	14.30	0.17	5.56	(33.58)	(7.93)
		(16.97)	(321.44)	268.65	(238.79)	590.46	811.41
XIV	Paid up Equity Share Capital (FV Rs.10/- each)	3,569.00	3,569.00	3,569.00	3,569.00	3,569.00	3,569.00
XV	Other Equity	-	-	-	-	-	6,786.02
	Basic and diluted earnings per share	(0.00)	(0.94)	0.75	(0.68)	1.74	2.22



Notes:

1. The above Unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 29th January 2026.
2. The Company operates in one business segment i.e. "Pharmaceuticals".
3. The figures for the previous year have been regrouped / rearranged wherever considered necessary.
4. The Statutory Auditors have expressed an unqualified opinion on the Unaudited Consolidated financials results for the quarter and Nine Month ended 31st December, 2025.
5. During the quarter under review, the Company has paid a premium of ₹217.14 lakhs on 1,08,570 preference shares, redeemed on 30th September 2025. The said premium has been adjusted against the General Reserve.
6. Effective from 21st November 2025, the Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes. On the basis of best available information, the Company has assessed the one time incremental impact of Rs. 11.41 Lakhs in the above financial results under Employee Benefit Expenses for the quarter and nine months ended 31st December 2025. The Company continues to monitor the finalisation of Central / State Government Rules and clarifications in relation to newly introduced Labour Code and would provide appropriate accounting effect if any on the basis of new developments.

For Lyka Labs Limited



Kunal Gandhi
Managing Director & CEO
DIN: 01516156



Mumbai : 29th January 2026



A handwritten signature in blue ink, appearing to read "Kunal Gandhi".